New Drug Combo to Battle Thyroid Cancer

Share this:

There's promising news in the battle against anaplastic thyroid cancer (ATC), a rare but aggressive and devastating form of thyroid cancer that typically strikes men and women in their 60s and 70s. The median survival is about 5 months from time of diagnosis.

A Mayo Clinic-led study, published in the journal Science Translational Medicine , reveals the combination of pazopanib and paclitaxel can slow the cancer growth. 

Click here for news release

Sound bites with lead researcher, Keith Bible, M.D.,Ph.D., are available in the downloads above

Expert title for broadcast cg: Dr. Keith Bible, Mayo Clinic Oncologist

Related Articles

Neurosciences

Mayo Clinic Minute: Treatment and research of glioblastoma

Cancer

Esophageal cancer — know the signs and reduce your risk

Cancer

Teamwork and a new nickname inspire patient through pancreatic cancer treatment